This episode, I walk through why StarHub just moved almost eight percent on something that is still only a research thesis, a possible M1 acquisition, not a confirmed transaction. We unpack the synergies DBS Group Research is modelling, around 9 to 11 percent of combined earnings and a S$1.40 target price, then separate that legitimate math from the hard reality that neither StarHub nor M1 has actually filed anything yet. From there, we widen the lens to this week’s STI gainers and losers, including AEM’s Zone 5, Red Zone yield-structure verdict, and wrap with Singapore’s labour market adding 10,700 jobs even as retrenchments rise to 4,500. If you are managing CPF or SRS, this is a kopi-length guide to telling the difference between a good story, a confirmed deal, and real income.
Key takeaways:
StarHub’s upgrade to “buy” with a S$1.40 target is built on a possible M1 deal, not a signed acquisition.
DBS is modelling merger synergies worth roughly 9 to 11 percent of combined FY2026 earnings, plus sector-wide ARPU uplift, but all of that depends on a deal actually happening.
AEM remains Iggy’s Forensic Zone: Zone 5, Red Zone, a fortress balance sheet with a trailing yield around 0.14 percent that fails every retirement income test in this framework.
Singapore’s labour market added about 10,700 jobs in Q2 2026, marking 19 straight quarters of growth, even as retrenchments climbed to 4,500, the highest since late 2020.
Week-on-week, several names gave back earlier chip rally gains, while others like DFIRG and Jardine C&C extended strong moves, useful context for any CPF or dividend investor watching volatility.
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
